CG Oncology (NASDAQ:CGON - Get Free Report)'s stock had its "buy" rating reissued by stock analysts at Bank of America in a research note issued to investors on Tuesday, Benzinga reports. They presently have a $65.00 price objective on the stock. Bank of America's price objective points to a potential upside of 84.45% from the stock's previous close.
Several other equities research analysts have also recently issued reports on CGON. Royal Bank of Canada initiated coverage on CG Oncology in a report on Monday, September 23rd. They set an "outperform" rating and a $66.00 price objective on the stock. HC Wainwright reissued a "buy" rating and issued a $75.00 price target on shares of CG Oncology in a research note on Tuesday, September 17th. Roth Mkm began coverage on shares of CG Oncology in a research note on Tuesday, August 27th. They set a "buy" rating and a $65.00 price objective for the company. Finally, Roth Capital upgraded shares of CG Oncology to a "strong-buy" rating in a report on Tuesday, August 27th. Seven equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, CG Oncology has an average rating of "Buy" and a consensus target price of $64.43.
View Our Latest Report on CGON
Shares of CG Oncology stock traded down $0.24 on Tuesday, hitting $35.24. The company's stock had a trading volume of 135,090 shares, compared to its average volume of 686,012. CG Oncology has a 52-week low of $25.77 and a 52-week high of $50.23. The firm has a fifty day moving average price of $35.70 and a 200-day moving average price of $35.17.
CG Oncology (NASDAQ:CGON - Get Free Report) last released its quarterly earnings results on Thursday, August 8th. The company reported ($0.28) EPS for the quarter, beating the consensus estimate of ($0.42) by $0.14. The business had revenue of $0.11 million during the quarter. On average, equities research analysts predict that CG Oncology will post -1.47 EPS for the current fiscal year.
In related news, Director Hong Fang Song sold 650,455 shares of the business's stock in a transaction that occurred on Thursday, August 29th. The stock was sold at an average price of $35.36, for a total transaction of $23,000,088.80. Following the transaction, the director now directly owns 586,982 shares of the company's stock, valued at approximately $20,755,683.52. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.
Several hedge funds and other institutional investors have recently bought and sold shares of CGON. BNP Paribas Financial Markets acquired a new stake in shares of CG Oncology during the first quarter worth approximately $492,000. Capstone Investment Advisors LLC bought a new stake in CG Oncology in the first quarter valued at about $806,000. TimesSquare Capital Management LLC bought a new stake in CG Oncology in the first quarter valued at about $9,837,000. Vanguard Group Inc. acquired a new stake in CG Oncology during the first quarter valued at approximately $97,678,000. Finally, Ameritas Investment Partners Inc. bought a new position in CG Oncology during the 1st quarter worth approximately $102,000. 26.56% of the stock is currently owned by hedge funds and other institutional investors.
CG Oncology, Inc, an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider CG Oncology, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CG Oncology wasn't on the list.
While CG Oncology currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.